Fulcrum Therapeutics, Inc. (FULC)
| Market Cap | 467.10M +141.0% |
| Revenue (ttm) | n/a |
| Net Income | -76.12M |
| EPS | -1.14 |
| Shares Out | 66.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,874 |
| Open | 6.88 |
| Previous Close | 6.88 |
| Day's Range | 6.88 - 7.08 |
| 52-Week Range | 4.78 - 15.74 |
| Beta | 3.01 |
| Analysts | Buy |
| Price Target | 16.38 (+133.67%) |
| Earnings Date | Apr 27, 2026 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for FULC stock is "Buy." The 12-month stock price target is $16.38, which is an increase of 133.67% from the latest price.
News
Fulcrum Therapeutics Earnings Call Transcript: Q1 2026
Positive phase I-B data for pociredir in sickle cell disease showed robust HbF increases and reduced VOCs, with strong safety and a solid cash runway into 2029. A registration-enabling trial is planned for the second half of 2026, pending FDA feedback.
Fulcrum Therapeutics reports Q1 EPS (25c), consensus (30c)
As of March 31, cash, cash equivalents, and marketable securities were $333.3M, compared to $352.3M as of December 31, 2025. The decrease of $19M was primarily due to cash used
Fulcrum Therapeutics CFO Alan Musso to retire
CFO Alan Musso plans to retire later this year to spend more time with his family and other outside interests. Musso will remain in his role until a successor is
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlu...
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve...
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
Leerink thinks Agios Pharmaceuticals’ (AGIO) announcement that it is filing mitapivat for accelerated approval in sickle cell disease has positive readthrough to Fulcrum Therapeutics (FULC) by demonst...
Fulcrum Therapeutics enters partnership for emergency sickle cell disease care
Fulcrum Therapeutics (FULC), MedicAlert Foundation, a nonprofit providing medical IDs and emergency medical information services, and Sickle Cell Disease Association of America, or SCDAA, the national...
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis Three-year collaboration is aimed at enhancing a key aspect of sickle cell m...
Fulcrum Therapeutics Transcript: Leerink Global Healthcare Conference 2026
PIONEER study data showed strong HbF induction, VOC reduction, and a favorable safety profile, generating positive feedback and interest for future trials. The next step is a pivotal registrational study with interim analysis for accelerated approval, while business focus remains on sickle cell disease and U.S. commercialization.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o...
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to imp...
Fulcrum Therapeutics price target lowered to $17 from $18 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Fulcrum Therapeutics (FULC) to $17 from $18 and keeps a Buy rating on the shares. The firm caught up with
Fulcrum PIONEER data reinforce pociredir differentiated profile, Wainwright says
Keeping a Buy rating on Fulcrum Therapeutics (FULC), H.C. Wainwright views the full 12-week data from the 20 mg cohort of the PIONEER study as encouraging and supportive of pociredir’s
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel
Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” and looks “overdone.” While the firm believes some thought total mean HbF
Truist remain buyers of Fulcrum Therapeutics shares on weakness
After Fulcrum Therapeutics (FULC) disclosed full Cohort 4 data from the Phase Ib PIONEER study for pociredir in sickle cell disease, Truist notes that mean absolute HbF was 19.3% and
Fulcrum Therapeutics Earnings Call Transcript: Q4 2025
The 20-mg cohort in the PIONEER trial showed robust HbF induction, improved anemia and hemolysis, and encouraging VOC reduction, with pociredir well-tolerated and poised for late-stage trials. Plans are underway for global expansion and regulatory engagement.
Fulcrum Therapeutics announces results from Phase 1b PIONEER trial of pociredir
Fulcrum Therapeutics (FULC) reported positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Key points: Mean absolute fetal
Fulcrum Therapeutics reports Q4 EPS (31c), consensus (30c)
“Building on the previously reported interim data presented in December at ASH, the positive 12-week data from the complete 20 mg cohort of the PIONEER trial reinforce our conviction in
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular H...
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve th...
Fulcrum Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Pociredir, an oral fetal hemoglobin inducer, showed robust HbF increases and improved clinical markers in sickle cell patients, with over half reaching transformative HbF levels and a strong safety profile. A registrational phase 3 study and open-label extension are planned for 2024.
Fulcrum Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Fulcrum Therapeutics (FULC) with an Overweight rating and $20 price target The recent Phase 1b data of pociredir in sickle cell disease “de-risks” the program from
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve th...